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Abstract MDPBP (1-(3,4-methylenedioxyphenyl)-2-(1-
pyrrolidinyl)-1-butanone) is a new psychoactive substance
sold on the black market. It has been a controlled drug of
abuse in Poland and China since 2015 as some toxic and
fatal cases connected with use of synthetic cathinone
derivatives were observed. The fatal case outlined here
concerns a 19-year-old man, who was found dead with an
envelope containing white powder lying nearby the cada-
ver. The analyses of the powder revealed a presence of
MDPBP. Due to this, blood was tested for routine toxico-
logical analysis for traditional drugs and for MDPBP by
liquid–liquid extraction procedure with 1-chlorobutane
followed by GC–MS analysis. Full validation of proposed
method was performed. Limit of detection and limit of
quantification were 10.1 and 30.4 ng/cm3, respectively.
Calibration curve was linear in studied concentration range
(25–1000 ng/cm3) with a correlation coefficient 0.9946.
The trueness and inter-day precision expressed as recov-
eries and CV values were investigated at 3 concentrations:
25, 250, and 1000 ng/cm3. The CV values were less than
20 % in the lowest concentration and less than 15 % in
other concentrations what met the internationally estab-
lished acceptance criteria for bioanalytical methods. It
indicates good precision and accuracy of the method. The
analysis of blood sample showed very high concentration
of MDPBP (9.32 lg/cm3), which suggests possibility of
overdosing. To the best of our knowledge, this is the first
work which presents determination of MDPBP in blood by
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Introduction
The interest in synthetic cathinone derivatives is a
reflection of their diverse range of biologically active
properties. Synthetic cathinones can stimulate central
nervous system. Therefore, medicinal exploration of
cathinone derivatives is not surprising. One of the phar-
macological properties of these compounds is the
inhibition of monoamine uptake transporters. It makes
them an interesting target for therapeutic applications,
e.g., antidepressant therapy, neurodegeneration, drug
addiction, and smoking cessation. However, a number of
cathinone derivatives offer also psychostimulatory and
entactogenic properties and are extensively available on
black market as new psychoactive substances (NPS)
& Mateusz K. Woz´niak
womat90@gmail.com
1 Chair and Department of Forensic Medicine, Faculty of
Medicine, Medical University of Gdan´sk, Gdan´sk, Poland
2 Department of Analytical Chemistry, Faculty of Chemistry,
Gdan´sk University of Technology, Gdan´sk, Poland
123
Monatsh Chem (2016) 147:1415–1421
DOI 10.1007/s00706-016-1780-0
under the names: ‘‘legal highs’’, ‘‘designer drugs’’, ‘‘re-
search chemicals’’, ‘‘bath salts’’, or ‘‘plant food’’.
Synthetic cathinones represent approximately two thirds
of the NPS available in the new drug market [1].
Recently, there has been a significant rise in the popu-
larity of these compounds especially among young people
on account of their stimulant properties and due to the
fact that they are perceived to be pure and safe [2]. A
novel group of these drugs as beta-ketone amphetamine
analogs contain a-pyrrolidinophenone unit originated in
China and, to a lesser extent, in India and in Europe [3–
5]. Structures of some drugs contain a-pyrrolidinophe-
none unit are presented in Scheme 1 and Table 1.
MDPBP (30,40-methylenedioxy-a-pyrrolidinobutyrophe-
none) is a psychoactive compound developed in the 1960s.
It is available for sale since 2009 (e.g., via the internet or in
black market shops) as one of the novel designer drugs. It is
usually mixed with flephedrone, pentedrone, pentylone,
MPPP, and MDPV. Its presence was confirmed in the seized
‘‘legal highs’’, such as: White Fiz, Vanilla Sky, and Bath
Salts. Psychoactive dose of MDPBP which affects central
nervous system, ranges from 50 to 100 mg. It is also usually
standard dose which is taken by abusers. MDPBP is the
most commonly administered via oral ingestion, nasal
insufflations, smoking, or intravenous injections. The
pharmacokinetics and psychoactive effects of this drug
have not been fully researched yet, but according to testi-
mony of its users, they are similar to ephedrine,
amphetamine, cocaine and to other substances containing a-
pyrrolidinophenone unit. Its use has been reported to cause
states of euphoria, agitation, hallucinations, and aggressive
behavior. Overdoses cause confusion, acute poisoning,
increase heart rate, high blood pressure and finally may lead
to arrhythmia, myocardial ischemia, and death [5–7].
The case described herein concerns a 19-year-old man
who was found dead and naked on the field. Small bag with
white powder was also found nearby. It was believed, that
the powder had been taken by the man before death.
However, his friends testified that the deceased was on the
party the day before accident, but he unexpectedly fled.
They also reported that man had drunk only approximately
100 cm3 of vodka and the drugs were not used during the
party. The victim was not agitated or aggressive. Moreover,
according to his father declarations the young man did not
have a habit of taking drugs or high doses of alcohol.
Analysis of the powder by mass spectrometry methods
revealed the presence of MDPBP as the only psychoactive
compound in the powder. Due to necessity of confirmation
of MDPBP intake by victim before death, the aim of this
study was to identify and determinate the concentration of
MDPBP in blood obtained during autopsy. However,
abusers often take more than one drug. Therefore, blood
sample was also investigated for psychoactive classical
drugs: amphetamine, methamphetamine and their deriva-
tives, cannabinoids, opiates, benzodiazepines, cocaine and
their metabolites by ELISA immunoenzymatic test (Neo-
gen) as it is performed during routine toxicology analysis.
The screening test was positive for cannabinoids. There-
fore, the identification and quantification of D9-
tetrahydrocannabinol (D9-THC) and its main metabolite
11-nor-D9-tetrahydrocanabinol-9-carboxylic acid (THC-
COOH) by derivatization and gas chromatography negative






Table 1 Structures of some drugs contain a-pyrrolidinophenone unit [4]
Name (CAS number; IUPAC name) R1 R2 R3
Alpha-PPP (19134-50-0; (RS)-1-phenyl-2-(1-pyrrolidinyl)-1-propanone) H CH3 H
MPPP (1313393-58-6; (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-propanone) CH3 CH3 H
Pyrovalerone (3563-49-3; (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-pentan-1-one) CH3 C3H7 H
MPBP (1214-15-9; (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-butanone) CH3 C2H5 H
Alpha-PVP (14530-33-7; (RS)-1-phenyl-2-(1-pyrrolidinyl)-1-pentanone H C3H7 H
MDPPP (24698-57-5; (RS)-1-(3,4-methylenedioxyphenyl)-2-(1-pyrrolidinyl)-1-propanone –O–CH2–O–
(R1–R3)
CH3 –
MDPBP (24622-60-4; (RS)-1-(3,4-methylenedioxyphenyl)-2-(1-pyrrolidinyl)-1-butanone) –O–CH2–O–
(R1–R3)
C2H5 –
MDPV (687603-66-3; (RS)-1-(benzo[d][1,3]dioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one) –O–CH2–O–
(R1–R3)
C3H7 –
1416 M. Wiergowski et al.
123
and electron impact ionization (GC-EI-MS) analysis,
respectively, according to developed method by Kała and
Kochanowski, was also performed [8].
Results and discussion
Method validation
Full validation of the method was performed. No MDPBP,
rac-methamphetamine-D5 (mAMP-D5) as an internal
standard (IS), and additional peaks due to endogenous
substances that could have interfered were reported in
blank samples and in samples investigated for selectivity at
the retention times of the analytes (Fig. 1). No carry-over
effect was observed. Therefore, investigated method is
characterized by high specificity and can be applied for
determination of MDPBP in blood. The data of calibration
curves to establish matrix effect (ME) were summarized in
Table 2.
The value of ME below 100 % indicates suppression of
signal by co-extracted compounds. In view of significant
matrix effect, calibration curve prepared in blood instead of
external calibration is recommended. To compensate the
variability of the detector responses during analysis and
losses of analytes in the extraction and sample preparation
steps (correction of recovery), the internal standard cali-
bration was performed. The calibration curve demonstrated
Fig. 1 a GC-EI-MS-SCAN chromatogram for mixture of IS solution
with standard solution of MDPBP (500 ng/cm3) in methanol (upper
chromatogram) and chromatogram obtained by GC-EI-MS-SIM for
the extracted blank blood sample used to validation procedure (lower
chromatogram); b EI-MS (70 eV) proposed mass spectral fragmen-
tation pattern of MDPBP
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a linear fit with a correlation coefficient 0.9946 in the
studied concentration range (25–1000 ng/cm3). The limit
of detection (LOD) and limit of quantification (LOQ)
values were 10.1 and 30.4 ng/cm3 for weighted linear
calibration curve. The following regression parameters
were obtained: a = 0.00099; b = 0.031; Sa = 0.000019;
Sb = 0.0034. The values of recoveries and CV for trueness
and inter-day precision were summarized in Table 3.
The recovery data and CV values showed that proposed
method is characterized by high accuracy and precision.
Moreover, the mean values of CV are less than 20 % in the
lowest concentration and less than 15 % in other concen-
trations what met the internationally established acceptance
criteria for bioanalytical methods [9, 10].
Analysis of real samples
The chemical and toxicological study of postmortem blood
samples revealed concentration of MDPBP—9.32 lg/cm3.
Additionally, in blood samples psychoactive D9-THC was
detected below LOQ level (\0.001 lg/cm3) and its inactive
main metabolite THC-COOH (0.006 lg/cm3) was quantified.
Very high level of MDPBP in blood confirmed that high
dose of this drug has been intaken before death. This may
suggest overdose of this drug what probably finally con-
tributed to victim’s death. The presence of small amount of
cannabinoids’ metabolite proves early hashish or marijuana
use with no significant effect of these toxic substances.
Fatal cases caused by overdose of cannabinoids are very
rare and often associated with taking other psychoactive
substances at the same time. Moreover, there are very little
data about the human pharmacokinetics and pharmacody-
namics of MDPBP. Therefore, there is no information in
the literature about interaction of synthetic cathinones and
cannabinoids. It can be easily explained by the fact that
these drugs are antagonists and interact with different
receptors in human organism. Cannabinoids affect recep-
tors CB1 and CB2 while cathinones, similar to
amphetamines, inhibit monoamine uptake receptors and
exert stimulant effect (increasing concentration of cate-
cholamines). However, taking marijuana causes reduction
of mental functioning what may lead to taking other drugs
in uncontrolled doses [7, 11].
To our best knowledge, this is the first work that pre-
sents determination of MDPBP in blood by GC-EI-MS
method and the third fatal accident confirmation of
MDPBP abuse. The first fatal case was reported in the UK
in 2011 and there was 1.55 lg/cm3 of MDPBP in victim’s
blood determined [12]. The second one was also reported
in Poland in 2014 and concerned a 19-year-old man [6].
Toxicological examination by LC–MS/MS technique
revealed a concentration of MDPBP in blood 7.01 lg/cm3,
which is comparable to the result obtained in our case
(9.32 lg/cm3). Those authors also reported case of four
drivers controlled by the Police, because of suspicions of
driving under the influence of drugs. Analysis of blood
samples collected from these drivers showed the concen-
tration of MDPBP ranging from 22 to 92 ng/cm3. Above-
mentioned, fatal concentrations of MDPBP were even
hundred times higher than values determined in blood of
drivers suspected of driving under the influence of drugs.
Another confirmation case of MDPBP abuse, but non-fatal,
was reported in Czech Republic in 2013 [13]. A 36-year-
old man, who was treated for his long-term ethanol
addiction and a habit of experimenting with new drugs
available in the local black market shops, admitted to have
taken an illegal powdered drug that was distributed under
the name ‘‘Funky’’, to overcome the symptoms of ethanol
withdrawal. In his urine MDPBP and 30-hydroxy-40-
methyl-a-pyrrolidinobutyrophenone as well as 40-hydroxy-
30-methyl-a-pyrrolidinobutyrophenone, in view of com-
mon m/z value on mass spectra, was detected. These two
Table 2 Calibration curve’s
equations for standard solutions
and blood’s extracts spiked with
analytes in the concentration
range 25–1000 ng/cm3




Methanol y = 0.0013x - 0.0041 0.9904 0.692 69.2
Blood’s extracts y = 0.0009x ? 0.025 0.9965
Table 3 Trueness and inter-day
precision of assay
Recovery (CV)/% (n = 6)
Concentration/ng cm-3 Trueness Inter-day
precision
Day 1 Day 2 Day 3
25 99.4 (9.2) 103.0 (4.2) 102.7 (9.5) 101.8 (7.5)
250 109.8 (9.2) 107.2 (1.1) 105.9 (2.0) 107.7 (5.5)
1000 92.4 (5.1) 94.7 (4.1) 92.1 (1.9) 93.1 (3.9)
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compounds were recognized as main metabolites of
MDPBP. Suggested metabolic pathway was similar to
proposed schemes by Zaitsu et al. obtained by
demethylenation followed by O-methylation [14].
Conclusion
Although various human sample matrices are available in
forensic toxicology analysis, blood is of the first choices
being a reference biological material, and one of the most
commonly used matrixes for drug determination with
possibility of quantitative and qualitative interpretation.
However, the determination of drugs in blood proves
merely taking drugs without the possibility to estimate the
route of administration (it is usually estimated based on
the analysis of various biological materials). Due to the
rapidly growing numbers of new psychoactive substances
available on black market and the large variability of the
drugs in structure and in concentration, the forensic
investigation of intoxications or fatalities is relatively
difficult. Therefore, new methods with fully validated
procedure for the analysis of novel drugs are of the
utmost importance.
Low limit of quantification, high recoveries, and good
repeatability of results make proposed method for the
determination of MDPBP in blood sufficient for identifi-
cation both fatal and toxic cases with even small
concentrations of MDPBP. It provides to be applicable in
comprehensive forensic investigations.
Experimental
Methanolic solution of 3,4-methylenedioxy-a-pyrrolidino-
butiophenone hydrochloride (MDPBPHCl) at concentration
1.0 mg/cm3 (as a free base) was purchased from Cayman
Chemicals (Ann Arbor, MI, USA) and rac-metham-
phetamine-D5 (mAMP-D5) at concentration 0.1 mg/cm
3 was
obtained from LGC Standards (London, United Kingdom).
Both solutions were used as standards.
All solvents used were of HPLC grade purity and were
obtained from SIGMA ALDRICH (St. Louis, USA). Tri-
fluoroacetic anhydride (TFAA) and 1-chlorobutane were
C99 % purity (analytical grade) and were also purchased
from SIGMA ALDRICH. Deionized water was purified
with a Synergy 185 ultra-pure water system (Millipore,
Milford, MA, USA). Hydrochloric acid at concentration
35–38 %, potassium carbonate (K2CO3), and sodium
chloride (NaCl) were of analytical grade and were obtained
from POCH (Gliwice, Poland). The 5 mol/dm3 K2CO3 and
saturated NaCl solutions were prepared by dissolving
above-mentioned salts in deionized water.
Samples
Blood samples were obtained during autopsy and were
stored at ?4 C before the analysis. For method validation
purpose blood was obtained from the local blood bank
(Gdan´sk, Poland) from subjects without drug history.
When analyte concentration in a sample was initially
higher than the calibration curve range, the sample was
diluted with drug-free blood, the extraction procedure was
performed again and extract was re-injected.
Preparation of standard and calibration solutions
Standard of MDPBPHCl was diluted with methanol to
make 25 lg/cm3 stock solution. Purchased mAMP-D5
standard solution was used as the internal standard (IS).
mAMP-D5 was chosen as IS in view of that it does not
occur naturally in the body fluids and that deuterated form
of MDPBP was not commercially available. The calibra-
tion solutions were prepared by mixing appropriate amount
of the stock solution with drug-free blood to obtain con-
centrations 25, 50, 100, 250, 500, 1000 ng/cm3. The added
volume of IS standard solution at concentration 0.1 mg/
cm3 to each sample was 5 mm3. Finally, the whole
extraction procedure was performed.
Sample preparation
Sample preparation was performed using modified method
according to in-house prepared method for the determina-
tion of amphetamines and piperazines in blood and urine
by liquid–liquid extraction procedure with derivatization
followed by GC-EI-MS analysis. Blood (1 cm3), standard
solution of IS (5 mm3), K2CO3 at concentration 5 mol/dm
3
(2 cm3), saturated NaCl (2 cm3), and acetonitrile (2 cm3)
were added to the screw-capped glass centrifuge tube.
The tube was vortex-mixed for 1 min. Subsequently,
1-chlorobutane (2 cm3) was added and sample was vortex-
mixed for 2 min. The solution was centrifuged for 3 min at
3000 rpm. The top layer was then transferred to a new
glass tube. An additional 2 cm3 of 1-chlorobutane were
added to the blood after first extraction, the tube was
vortex-mixed for 2 min and then centrifuged for 3 min at
speed 3000 rpm. The top layer was added to tube con-
taining the first extracts. The bottom layer was discarded.
Then 100 mm3 of hydrochloric acid solution in methanol
(1:9, v/v) was added. Then, extracts were evaporated to
dryness with an inert gas stream (nitrogen) at 40 C and
reconstituted in 50 mm3 ethyl acetate. Derivatization was
performed with 50 mm3 TFAA (20 min, 55 C). Finally,
solution was evaporated to dryness and residue was dis-
solved in 50 mm3 of ethyl acetate. An aliquot of 2 mm3
volume was injected into the GC–MS system.
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Instrumentals
The chromatographic separation was carried out using
Trace GC gas chromatograph equipped with autosampler
AS 3000, split/splitless injector and mass spectrometry
detector Trace DSQ (Thermo Finnigan). The analytes were
separated on capillary column ZB-5 MS 30 m 9 0.25 mm
i.d., 0.25 lm film thickness (Phenomenex) with helium as a
carrier gas (1.0 cm3/min). Split injection mode was used
(10:1). The oven temperature was programmed as follows:
1 min at 50 C, then 30 C/min up to 160 C, 10 C/min
ramp up to 250 C, and finally 30 C/min ramp to 300 C.
Post-run conditioning was set at 300 C for 10 min in order
to eliminate carry-over effect. Inlet and detector mass
spectrometry (MS) source ions temperatures were 260 and
280 C, respectively. For full-scan acquisition, the MS was
operated in positive electron impact mode (electron energy
70 eV) and the mass detection range was m/z 30–380. The
following ions were chosen for selected ion monitoring
mode (SIM) for identification and quantification: MDPBP,
m/z 70, 149, 112; IS, 158, 113, 119. The underlined ions
were used for quantification. These ions were chosen on the
basis of their abundance and that they were also among the
most specific ions present.
Validation procedure
Full validation is important for a new drug entity and for
proper toxicological interpretation and establishing new
references criteria. The method was validated following the
accepted criteria for bioanalytical method validation [9,
10]. We evaluated selectivity, matrix effect, linearity, limit
of detection (LOD), limit of quantification (LOQ), carry-
over effect, trueness, recovery, and repeatability.
Selectivity, calibration curve and matrix effect
Selectivity experiments were carried out with six blood
samples obtained from various subjects to confirm that no
substances were present in the retention times of analyte
and internal standard. The whole extraction procedure was
performed and extracts were injected to GC–MS system.
Six-point calibration curve (25, 50, 100, 250, 500, and
1000 ng/cm3) was constructed in triplicate by plotting the
ratio of the MDPBP peak area to the peak area of the IS
versus the MDPBP concentrations. Two calibration curves
have been done according to Matuszewski et al. [15]:
solutions of analyte were prepared in methanol as well as in
extracts obtained from drug-free blood to determine matrix
effect and decide which calibration approach should be
applied. Matrix effect was calculated as follows (Eq. 1)
[15]:
ME %½  ¼ am
as
100 % ð1Þ
where am is the slope in extracts spiked with analytes, and
as is the slope in solvent.
Linearity, limit of detection (LOD), limit
of quantification (LOQ)
The linearity was investigated in concentration range
25–1000 ng/cm3. The weighing factor of 1/x was applied to
calibration curve in order to increase the accuracy in the
lower concentration range. The limit of detection (LOD) was
established based on following formula: LOD = 3.3Sb/a,
where Sb is the standard deviation of the intercept and a is the
slope of the calibration curve. The limit of quantification
(LOQ) was calculated as three times LOD value [16].
Carry-over effect, trueness, recovery,
and repeatability
The carry-over test was performed by injection to GC–MS
system the highest concentration of analyte from the cali-
bration curve followed by methanol solution. The test was
performed six times. The trueness of the results was mea-
sured by recoveries using spiked blood as a matrix at three
different concentration levels (low-25, medium-250, and
high-1000 ng/cm3). Each sample was analyzed in sixfold
on the same day (n = 6). Repeatability was assessed as
inter-day precision by analyzing blank blood samples also
spiked at the above-mentioned tree concentration levels
(low, medium, and high). The analyses were repeated
during the next three consecutive days. Inter-day repeata-
bility was expressed as recovery and CV of between-days
averages. Each sample was analyzed in sixfold each day.
The results obtained by comparing the analyte to IS peak
area ratio for the spiked and extracted blank blood samples
with the corresponding extracts spiked with standard
solutions of analyte (matrix-match calibration curve). In all
cases, internal standard was spiked post-extraction to avoid
its loss during extraction.
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